Stifel Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Hold, 'Stock Might Even Be Too Cheap, But It's Getting Harder to See the Path'
Tweet Send to a Friend
Stifel analyst Paul Matteis downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Buy to Hold with a price target of $61.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
